BrainCells

About:

BrainCells is a biotechnology startup focused on drugs intended to stimulate the growth of new neurons.

Website: http://www.braincellsinc.com

Top Investors: New Enterprise Associates, Alexandria Real Estate Equities, Oxford Bioscience Partners, Bay City Capital, Technology Partners

Description:

BrainCells develops and provides biopharmaceutical products for the treatment of central nervous system (CNS) diseases. It develops compounds that promote the growth of new neurons for the treatment of major depressive disorder (MDD), treatment resistant depression (TRD), and potentially Alzheimer’s disease (AD). The company's products include BCI-838 and BCI-632 which increase synaptic glutamate by inhibiting the mGlu2/3 auto-receptor. The company also builds a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes, and other CNS disorders. The company was founded in 2003 and is based in San Diego, California.